A detailed history of Certified Advisory Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Certified Advisory Corp holds 7,436 shares of ABBV stock, worth $1.36 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
7,436
Previous 7,504 0.91%
Holding current value
$1.36 Million
Previous $1.29 Million 14.06%
% of portfolio
0.17%
Previous 0.17%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$163.84 - $199.33 $11,141 - $13,554
-68 Reduced 0.91%
7,436 $1.47 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $61,606 - $71,942
-398 Reduced 5.04%
7,504 $1.29 Million
Q1 2024

May 10, 2024

BUY
$159.82 - $182.1 $87,101 - $99,244
545 Added 7.41%
7,902 $1.44 Million
Q4 2023

Feb 09, 2024

BUY
$137.6 - $154.97 $3,302 - $3,719
24 Added 0.33%
7,357 $1.14 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $1,068 - $1,237
-8 Reduced 0.11%
7,333 $1.09 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $68,640 - $85,418
518 Added 7.59%
7,341 $989,000
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $59,000 - $67,948
408 Added 6.36%
6,823 $1.09 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $26,970 - $32,344
-195 Reduced 2.95%
6,415 $1.04 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $5,905 - $6,772
44 Added 0.67%
6,610 $887,000
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $8,807 - $11,197
64 Added 0.98%
6,566 $1.01 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $3,959 - $4,912
30 Added 0.46%
6,502 $1.06 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $3,652 - $4,621
34 Added 0.53%
6,472 $876,000
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $106 - $120
-1 Reduced 0.02%
6,438 $694,000
Q2 2021

Aug 16, 2021

SELL
$105.21 - $117.21 $5,050 - $5,626
-48 Reduced 0.74%
6,439 $725,000
Q1 2021

May 10, 2021

SELL
$102.3 - $112.62 $1,943 - $2,139
-19 Reduced 0.29%
6,487 $702,000
Q2 2020

Jul 27, 2020

BUY
$73.37 - $98.18 $116,805 - $156,302
1,592 Added 32.4%
6,506 $639,000
Q1 2020

Apr 27, 2020

BUY
$64.5 - $97.79 $6,772 - $10,267
105 Added 2.18%
4,914 $375,000
Q4 2019

Jan 29, 2020

SELL
$72.13 - $90.25 $62,753 - $78,517
-870 Reduced 15.32%
4,809 $426,000
Q3 2019

Nov 12, 2019

SELL
$62.98 - $75.72 $21,098 - $25,366
-335 Reduced 5.57%
5,679 $430,000
Q2 2019

Aug 07, 2019

BUY
$65.7 - $83.98 $8,475 - $10,833
129 Added 2.19%
6,014 $438,000
Q1 2019

May 07, 2019

BUY
$77.14 - $90.79 $40,652 - $47,846
527 Added 9.84%
5,885 $475,000
Q4 2018

Feb 04, 2019

BUY
$77.85 - $96.01 $22,887 - $28,226
294 Added 5.81%
5,358 $494,000
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $4,712 - $5,238
-53 Reduced 1.04%
5,064 $479,000
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $10,773 - $12,747
120 Added 2.4%
5,117 $474,000
Q1 2018

Apr 30, 2018

BUY
$92.01 - $123.21 $38,092 - $51,008
414 Added 9.03%
4,997 $472,000
Q4 2017

Feb 22, 2018

BUY
$89.56 - $98.21 $410,453 - $450,096
4,583
4,583 $442,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $324B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Certified Advisory Corp Portfolio

Follow Certified Advisory Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Certified Advisory Corp, based on Form 13F filings with the SEC.

News

Stay updated on Certified Advisory Corp with notifications on news.